ResAppDx-EU version two can now be used to diagnose respiratory disease in both adults and children. ResApp Health (ASX: RAP) has finally locked-in Australian Therapeutic Goods Administration for using its smartphone-based diagnostic technology to determine respiratory disease in adults. This latest milestone follows TGA approval in October to use its respiratory diagnostic technology in paediatrics . ResApp’s smartphone application ResAppDx-EU version two can now be used to diagnose respiratory disease in both adults and children and is approved as a Class IIa medical device which is now listed on the Australian Register of Therapeutic Goods. “We are pleased that our lead produce ReAppDx-EU is now approved for use on both adults and children in Australia and Europe,” ResApp chief executive officer and managing director Tony Keating said. ResAppDX-EU technology With most people developing an acute respiratory tract infection each year, it is the most common acute illness seen in […]